



(51) International Patent Classification:

C07D 401/06 (2006.01) A61K 31/4709 (2006.01)

C07D 471/04 (2006.01) A61P 29/00 (2006.01)

C07D 519/00 (2006.01)

(21) International Application Number:

PCT/US2012/026572

(22) International Filing Date:

24 February 2012 (24.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/446,902 25 February 2011 (25.02.2011) US

(71) Applicant (for all designated States except US): ARRAY BIOPHARMA INC. [US/US]; 3200 Walnut, Boulder, CO 80301 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLAKE, James, F** [US/US]; C/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US). **DELISLE, Robert, Kirk** [US/US]; C/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US). **DE MEESE, Lisa, A.** [US/US]; 2925 E. Riggs Road #8-176, Phoenix, AZ 85249 (US). **GRAHAM, James, M.** [US/US]; 1518 Chukar Drive, Longmont, CO 80501 (US). **LE HUEROU, Yvan** [FR/US]; 2775 Lee Hill Road, Boulder, CO 80302 (US). **LYON, Michael** [US/US]; C/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US). **ROBINSON, John, E.** [US/US]; C/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US). **WALLACE, Eli, M.** [US/US]; 404 Arborcrest Drive, Richardson, TX 75080 (US). **WANG, Bin** [CN/US]; 3434 Lovers Lane, Dallas, TX 75225 (US). **XU, Rui** [CN/US]; C/o Array Biopharma Inc., 3200 Walnut Street, Boulder, CO 80301 (US).

(74) Agents: **HARRIS, Robert, J.** et al.; Viksnins Harris & Padys LLP, P.O. Box 111098, St. Paul, MN 55111-1098 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS



(57) Abstract: Compounds of Formula I: in which R¹, R², R³, R⁴ and R¹⁰ have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.